This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2009 Sep;11(9):566-8.

Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement

Nina Avshovich¹, Nina Boulman, Gleb Slobodin, Abdel-Rauf Zeina, Itzhak Rosner, Michael Rozenbaum

Affiliations

Affiliation

¹ Department of Rheumatology, Bnai Zion Medical Center, and Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. rosneri@tx.technion.ac.il

PMID: 19960854

Free article

Case Reports

Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement

Nina Avshovich et al. Isr Med Assoc J. 2009 Sep.

Free article

. 2009 Sep;11(9):566-8.

Authors

Nina Avshovich¹, Nina Boulman, Gleb Slobodin, Abdel-Rauf Zeina, Itzhak Rosner, Michael Rozenbaum

Affiliation

¹ Department of Rheumatology, Bnai Zion Medical Center, and Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. rosneri@tx.technion.ac.il

PMID: 19960854

No abstract available

PubMed Disclaimer

Similar articles

Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report.
Ooka S, Maeda A, Ito H, Omata M, Yamada H, Ozaki S. Ooka S, et al. Mod Rheumatol. 2009;19(1):80-3. doi: 10.1007/s10165-008-0119-z. Epub 2008 Sep 18. Mod Rheumatol. 2009. PMID: 18806927
Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener's granulomatosis.
Tektonidou MG, Skopouli FN. Tektonidou MG, et al. Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S103. Clin Exp Rheumatol. 2006. PMID: 16859607 No abstract available.
Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases.
Dalkilic E, Alkis N, Kamali S. Dalkilic E, et al. Mod Rheumatol. 2012 Jun;22(3):463-6. doi: 10.1007/s10165-011-0507-7. Epub 2011 Aug 17. Mod Rheumatol. 2012. PMID: 21847703
S3. Rituximab for ANCA-associated vasculitides: the French experience.
Charles P, Guillevin L. Charles P, et al. Presse Med. 2013 Apr;42(4 Pt 2):534-6. doi: 10.1016/j.lpm.2013.01.050. Epub 2013 Feb 26. Presse Med. 2013. PMID: 23453207 Review. No abstract available.
Treatment of granulomatosis with polyangiitis (Wegener's).
Pagnoux C, Guillevin L. Pagnoux C, et al. Expert Rev Clin Immunol. 2015 Mar;11(3):339-48. doi: 10.1586/1744666X.2015.1008455. Epub 2015 Feb 2. Expert Rev Clin Immunol. 2015. PMID: 25644677 Review.

See all similar articles

Cited by

Non-infectious orbital vasculitides.
Perumal B, Black EH, Levin F, Servat JJ. Perumal B, et al. Eye (Lond). 2012 May;26(5):630-9. doi: 10.1038/eye.2012.28. Epub 2012 Feb 24. Eye (Lond). 2012. PMID: 22361845 Free PMC article. Review.
Rituximab for refractory granulomatous eye disease.
Lower EE, Baughman RP, Kaufman AH. Lower EE, et al. Clin Ophthalmol. 2012;6:1613-8. doi: 10.2147/OPTH.S35521. Epub 2012 Oct 5. Clin Ophthalmol. 2012. PMID: 23055686 Free PMC article.
The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.
Habibi MA, Alesaeidi S, Zahedi M, Hakimi Rahmani S, Piri SM, Tavakolpour S. Habibi MA, et al. Biology (Basel). 2022 Dec 6;11(12):1767. doi: 10.3390/biology11121767. Biology (Basel). 2022. PMID: 36552276 Free PMC article. Review.
Efficacy of Rituximab on Refractory Organ Involvements in Granulomatosis with Polyangiitis: A Systematic Review of Case Reports.
Hajishah H, Amini MJ, Chadeganipour AS, Salehi SA, Kazemi D. Hajishah H, et al. Curr Rheumatol Rev. 2024;20(3):270-283. doi: 10.2174/0115733971263964231020072640. Curr Rheumatol Rev. 2024. PMID: 37907486
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T; GRAID investigators. Tony HP, et al. Arthritis Res Ther. 2011 May 13;13(3):R75. doi: 10.1186/ar3337. Arthritis Res Ther. 2011. PMID: 21569519 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Israel Medical Association
Medical
- MedlinePlus Health Information